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Urothelial cancer (UC) is devastating disease, once it 
reaches muscle invasive (MIBC) and metastatic stage. Even 
when performing radical cystectomy (RC) with pelvic 
lymphadenectomy in patients with MIBC, approximately 
half of the patients will develop metastasis and still no long-
term cure for metastatic urothelial cancer (mUC) has been 
found (1). Neoadjuvant cisplatin-based chemotherapy is 
considered a standard approach in pT2-pT4a pN0 disease 
which can improve survival outcomes after surgery. Though, 
it is still underutilized. Platinum-based combination 
chemotherapies are also used to treat mUC in first line 
(2,3). Till 2016, the only approved second line drug for 
patients who failed during or after first line platinum-based 
chemotherapy was vinflunine. With limited treatment effect 
in a phase 3 trial compared to best supportive care (BSC), it 
has been approved in Europe only (4,5). In the US, taxane 
based chemotherapies were commonly used in this setting. 
Prior to approval of immune checkpoint inhibitors (CPI), 
the median overall survival (mOS) for metastatic UC was 
poor with around 15 months using first line cisplatin-based 
combination chemotherapies (2,3) and roughly 10 months 
for patients being ineligible for cisplatin, and therefore 
receiving carboplatin-based combination chemotherapy (6). 
Patients receiving second line chemotherapy after platinum-
based regimens reached a mOS of about 7 months (5).
With approval of the first CPI atezolizumab in 2016 in 
the second line setting, the treatment of mUC has changed 
dramatically (7). Although, response rates in unselected 
patient population are still not high, all substances have in 
common, that patients who respond to CPI treatment seem 
to have long-lasting responses, with the median duration 
of response (DoR) not being reached in most of trials 
(8-15). Several other targeting agents [i.e., erdafitinib (16), 
enfortumab vedotin (17)] are under evaluation in clinical 
trials and have shown promising results, that hopefully will 
enlarge treatment options in mUC and potentially in the 
neoadjuvant setting (18-20).
In first line setting, gemcitabine/cisplatin is still standard 
for metastatic and locally advanced, non-resectable mUC. 
Though, nearly half of patients are ineligible for cisplatin-
based chemotherapy, which is commonly defined by the 
criteria proposed by Galsky et al. (21). For cisplatin-
ineligible patients atezolizumab (9) and pembrolizumab (8) 
have been approved by the European Medicines Agency 
(EMA) and the North-American Food and Drug 
Administration (FDA) for patients with PD-L1 positive 
tumors, defined by the presence of PD-L1 positively stained 
cells and analyzed by either tumor infiltrating immune cells 
(IC) ≥5% or the combined positive score (CPS) ≥10 (22,23).
In second line, CPI have revolutionized the treatment 
mUC. Because of urgent medical need all substances were 
initially approved based on early phase I/II data independent 
of the PD-L1 status. In Europe, three substances are 
approved for treatment of mUC after failure of platinum-
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based chemotherapy [pembrolizumab (10), atezolizumab 
(13,24), and nivolumab (15)]. In addition, durvalumab (14) 
and avelumab (12) are approved in this indication in the 
US only.
Though, pembrolizumab is the only CPI with proven 
level 1 evidence from KEYNOTE-045 being superior to 
second line chemotherapy for mUC (10). In this trial, a 
total of 542 patients were randomly assigned to receive 
either pembrolizumab or investigators’ choice of second 
line chemotherapy (vinflunine, docetaxel or paclitaxel). In 
the initial NEJM publication, Bellmunt et al. presented a 
beneficial mOS of 10.3 [95% confidence interval (CI), 8.0–
11.8] months in the pembrolizumab group, as compared to 
7.4 (95% CI: 6.1–8.3) months in the chemotherapy group 
[hazard ratio (HR) for death, 0.73; 95% CI: 0.59 to 0.91; 
P=0.002]. In the total population, the objective response 
rate (ORR) was significantly higher in the pembrolizumab 
group  (21 .1%;  95% CI :  16 .4–26 .5 )  than  in  the 
chemotherapy group (11.4%; 95% CI: 7.9–15.8; P=0.001). 
Pembrolizumab showed less treatment-related events of 
grade 3–5 than second line chemotherapy (15.0% vs. 49.4% 
of patients), which resulted in lower rate of treatment-
related discontinuation of therapy (5.6% vs. 11.0%) (10). 
Recently, Fradet et al. published updated results of this 
trial with a >2 years follow up (11). The mOS is nearly 
unchanged with 10.1 months for the pembrolizumab 
group as compared to 7.3 months for patients treated with 
chemotherapy (HR 0.70, 95% CI: 0.57–0.85; P=0.00015). 
Interestingly, no statistically significant difference in 
progression free survival (PFS) between the pembrolizumab 
and chemotherapy arms has been observed (2.1 months; 
95% CI: 2.0–2.2 vs. 3.3 months; 95% CI: 2.4–3.6; HR 
0.96; 95% CI: 0.79–1.16). However, the 2-yr PFS rates 
were higher in pembrolizumab treated patients (12.4%) 
than in the group treated with chemotherapy (3.0%) (11). 
The median DoR to treatment in patients responded 
to chemotherapy (n=30) is only 4.4 months (range, 1.4+ 
to 29.9+ months), while is still has not been reached for 
patients initially responded to pembrolizumab (1.6+ to 
30.0+) (11). After a median follow-up of 27.7 months, this 
translates into one-year survival rates of 44.2% vs. 19.8% 
and two-year survival rates of 26.9% vs. 14.3% for patients 
treated with pembrolizumab vs. second line chemotherapy, 
respectively. Remarkably, the OS rate of 14.3% at 2 years 
for the chemotherapy arm, which hasn’t been observed 
in previous second line clinical trials, could possibly be 
explained by the fact, that the majority of patients alive at 
24 months (60.6%), received a third line CPI treatment (11). 
In terms of safety, treatment-related adverse events 
(AEs) occurred less frequently in patients receiving 
pembrolizumab (62.0%) than in chemotherapy treated 
patients (90.6%). The most common AEs were pruritus 
for the pembrolizumab arm and alopecia, fatigue, anemia, 
nausea, constipation, decreased appetite, and neutropenia 
for the chemotherapy arm (11). The longer follow-up 
confirmed data from the initial publication, underlining the 
safety and better tolerability of pembrolizumab compared 
to chemotherapy in this therapeutic setting.
Atezolizumab is the other CPI that has been evaluated 
in a second line, phase III clinical trial (IMvigor211) (13). 
The phase II trial IMvigor210 (cohort 2) showed promising 
results, with an impressive mOS of 11.4 months in 
patients with PD-L1 positive tumors (IC2/3), based on 
staining with the antibody SP142 and analysis of tumor 
infiltrating immune cells (IC ≥5%). Patients with low 
PD-L1 (IC1: ≥1% and <5%) or no PD-L1 (IC0: <1%) 
expression had significantly worse outcome with a mOS of 
6.7 (95% CI: 5.1–8.8) and 6.5 (95% CI: 4.4–8.3) months, 
respectively (24).
Though, the following IMvigor211 trial failed to proof 
superiority to second line chemotherapy (13). This large 
phase III clinical trial, enrolled 931 patients, who were 
randomly assigned to receive either atezolizumab or second 
line chemotherapy of investigators’ choice. The primary 
endpoint of overall survival was tested hierarchically in 
prespecified populations: IC2/3, followed by IC1/2/3, 
followed by the intention-to-treat population. 
The PD-L1 positive population (IC2/3) showed a 
comparable mOS of 11.1 (95% CI: 8.6–15.5) months (13) to 
the phase II data with 11.4 (95% CI: 9.0–NE) months (24), 
but the comparator arm showed a mOS of 10.6 (95% CI: 
8.4–12.2) months, which exceeded the study expectations 
based on the phase III trial evaluating vinflunine compared 
to BSC (4,5). This resulted in a not significant survival 
benefit (HR 0.87, 95% CI: 0.63–1.21; P=0.41).
Though, there are distinct differences between both 
phase III trials evaluating pembrolizumab (10,11) and 
atezolizumab (13) compared to second line chemotherapy 
(Table 1).
Comparison of KEYNOTE-045 and IMvigor211 
based on PD-L1 status
The ORR based on PD-L1 status showed distinct 
differences between both trials. In KEYNOTE-045, 21.6% 
of PD-L1 positive (CPS ≥10) and 21.1% of unselected 
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Table 1 Patient characteristics of phase III clinical trials evaluating pembrolizumab and atezolizumab in mUC
KEYNOTE-045 (10,11) IMvigor211 (13)













Age [range] 67 [29–88] 65 [26–84] 67 [43–88] 67 [36–84] 67 [33–88] 67 [31–84]
Primary tumor site
Bladder/urethra 85.9% 86.3% 75.0% 78.8% 71.3% 74.5%
Upper tract 14.1% 13.7% 25.0% 22.2% 28.7% 25.6%
Metastatic sites
Visceral 89.3% 86.0% 67.2% 69.5% 77.3% 76.5%
Liver 33.7% 35.1% 24.1% 25.4% 29.6% 28.0%
Lymph node only 10.4% 13.6% 15.5% 22.9% 11.6% 14.2%
PD-L1 status CPS <10 vs. ≥10 IC <5% (IC0/1) vs. ≥5% 
Positive 27.4% 33.1% 100% 100% 24.8% 25.4%
ECOG performance status
0 44.4% 39.0% 52.6% 48.3% 46.7% 44.6%
1 52.6% 58.1% 52.6% 51.7% 53.3% 55.4%
2 1.1% 1.5% 0.0% 0.0% 0.0% 0.0%
Number of risk factors
0 20.0% 16.5% 37.9% 34.7% 31.0% 30.2%
1 35.9% 37.5% 43.1% 40.7% 45.8% 44.8%
2 24.4% 29.4% 13.8% 21.2% 18.4% 20.7%
3–4 16.7% 16.5% 5.2% 3.4% 4.7% 4.3%
Previous systemic regimen setting
Neoadjuvant or adjuvant with 
progression within ≤12 months
11.5% 19.5% 31.9% 31.4% 25.1% 23.3%
First line 68.1% 58.1% 46.6% 50.0% 53.3% 56.3%
Second line 20.4% 21.7% 15.5% 15.3% 16.9% 15.9% 
Third line 0.0% 0.7% 0.9% 0.0% 1.7% 1.9%
Prior radical surgery 22.6% 18.8% 49.1% 49.2% 42.6% 43.1%
Chemotherapy on trial (safety population)
Vinflunine – 34.1% (87/255) – n.a. – 54.6% (242/443)
Docetaxel – 32.9% (84/255) – n.a. – 12.0% (53/443)
Paclitaxel – 32.9% (84/255) – n.a. – 33.4% (148/443)
Table 1 (Continued)
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patients responded to pembrolizumab, while the ORR 
to chemotherapy was lower with 11.4% and 6.7% in the 
total population and the CPS ≥10 intention-to-treat (ITT) 
population, respectively (10). Opposingly, response rates to 
atezolizumab were higher in the IC2/3 (IC ≥5%) population 
than in the unselected ITT population in IMvigor211 
(23.0% vs. 13.4%) (13). Interestingly, also the response 
to chemotherapy was better in patients with PD-L1 
positive tumors compared to unselected patients (21.6% vs. 
13.4%) (13). Unexpectedly, overexpression of PD-L1 
resulted in a more favorable outcome with increased ORR 
and longer overall survival for both, chemotherapy and 
atezolizumab in IMvigor211. This negates the potential 
predictive value of PD-L1, when stained with SP142 and 
analyzed for tumor infiltrating IC, and suggest a rather 
prognostic effect of PD-L1 in this setting (13).
In KEYNOTE-045 a significantly longer mOS for 
pembrolizumab over chemotherapy has been observed in 
unselected patients (10.1 vs. 7.3 months; 95% CI: 0.57–
0.85; HR 0.70) and patients harboring PD-L1 positive 
tumors (CPS ≥10) with 8.0 vs. 4.9 months (P=0.00122), 
respectively (11). Remarkable, in KEYNOTE-045 
PD-L1 expression (antibody 22C3; CPS ≥10) seems to 
have a negative prognostic effect, while in IMvigor211 
(antibody SP142; IC ≥5%) in seems to have positive 
prognostic properties.
Comparison of KEYNOTE-045 and IMvigor211 
based on second line chemotherapeutic agents
In KEYNOTE-045, pembrolizumab showed a mOS 10.1 
vs. 7.4 months in unselected patients for PD-L1 status and 
compared to second line chemotherapy of investigators’ 
choice (95% CI: 6.1–8.3) (10). Exploratory analysis of the 
IMvigor211 trial revealed a mOS of 8.6 (95% CI: 7.8–9.6) 
months for atezolizumab and 8.0 (95% CI: 7.2–8.6) months 
for second line chemotherapy in the ITT population (13). 
Further analysis, stratified by the choice of second line 
chemotherapy, showed a survival benefit of atezolizumab 
compared to taxane-based chemotherapy (docetaxel, 
paclitaxel) with a mOS of 8.3 vs. 7.5 months (HR 0.73; 95% 
CI: 0.58–0.92), but not over vinflunine with a mOS of 9.2 
vs. 8.3 months (HR 0.97; 95% CI: 0.78–1.19) (25). 
One of the major differences between both trials is the 
distribution of chemotherapeutic agents in the comparator 
arms. In IMvigor 211, the majority of patients in the 
chemotherapy arm (n=443) received vinflunine (55%), while 
paclitaxel (33%) and docetaxel (12%) where less frequently 
chosen by investigators in this trial (13). This might be 
related to the study population, with the majority of patients 
being recruited in Western Europe, where vinflunine is 
an approved second line chemotherapeutic agent (4,5). In 
KEYNOTE-045, distribution of chemotherapeutic agents 
was well balanced in the chemotherapy arm (10,11).
Comparison of KEYNOTE-045 and IMvigor211 
based on primary tumor and metastatic site
IMvigor211 included more upper tract urothelial tumors 
(UTUC) than KEYNOTE-045, which were evenly 
distributed between the treatment arms. While 25.3% of 
included patients in IMvigor211 had UTUC, only 13.8% of 
patients in KEYNOTE-045 harboring UTUCs (11,13). 
Rates of patients with visceral and liver metastases were 
higher in KEYNOTE-045 with 87.8% and 34.3% (11) 
compared to IMvigor211 with 68.4% and 24.8% in the 
Table 1 (Continued)
KEYNOTE-045 (10,11) IMvigor211 (13)













Subsequent treatment (ITT 
population)
25.2% 33.5% n.a. n.a. 23.1% 25.4%
Chemotherapy n.a. n.a. n.a. n.a. 21.6% 19.8%
Immunotherapy n.a. n.a. n.a. n.a. 1.3% 6.0%
Others n.a. n.a. n.a. n.a. 4.5% 1.7%
ITT, intention-to-treat; n.a., not available.
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IC2/3 and 76.9% and 28.8% in the ITT population (13). 
Patients with PD-L1 positive tumors (IC2/3) and liver 
metastasis showed a superior response to atezolizumab 
compared to chemotherapy in IMvigor211 (HR 0.51; 
95% CI: 0.28–0.96). Rates of patients with lymph nodes 
(LN) only disease were comparable between both trials 
with 12.9% (IMvigor211) and 12.0% (KEYNOTE-045) 
(11,13). Though, the chemotherapy arm in IMvigor211 
(IC2/3 population) included a higher rate of patients with 
LN only disease (22.9%) compared to only 15.5% in the 
PD-L1 positive population treated with atezolizumab (13). 
Nevertheless, this factor cannot explain the good response 
to chemotherapy in this trial, since LN only patients 
show favorable response to atezolizumab compared to 
chemotherapy in patients with PD-L1 positive tumors (HR 
0.60, 95% CI: 0.26–1.36) and even better in the unselected 
ITT population (HR 0.59; 95% CI: 0.37–0.96). 
Comparison of KEYNOTE-045 and IMvigor211 
based on risk factors and previous and 
subsequent off-study treatments
IMvigor211 and KEYNOTE-045 recruited different 
baseline population with lower rates of patients without 
any Bajorin risk factors in IMvigor211 (10,13). In addition, 
more patients underwent prior surgery of the primary 
tumor in IMvigor211 than in KEYNOTE-045, with 42.9% 
vs. 20.7%, respectively (10,13). This raises the question 
of whether presence of the primary tumor plays a role in 
response to CPI in mUC.
The higher rate of primary tumor resection also explains 
the higher rate of patients, who underwent previous 
neoadjuvant and adjuvant chemotherapy in IMvigor211 
(24.2% vs. 15.5%) compared to KEYNOTE-045 (10,13). 
This rate was even higher in the IC2/3 population of 
IMvigor211 with 31.6% of patients (13). In both phase III 
trials the rate of subsequent treatments was relatively high, 
with more than 20% of patients having received following 
treatments after on study treatment (10,11,13), which 
reflects the increasing therapeutic options for patients with 
mUC (Figure 1).
Both trials have evaluated a CPI in second line after 
failure of platinum-based chemotherapy. Though, 
comparison and interpretation of differences between those 
trials is difficult. These two, phase III trials studied distinct 
different patient populations, PD-L1 has been evaluated with 
different antibodies, staining platforms and scoring methods, 
and the comparator arms had a different distribution 
of second line chemotherapeutic agents (10,11,13). In 
addition, IMvigor211 used a biomarker driven design, using 
PD-L1 positivity in a hierarchal statistical design of several 
subgroup analysis (13). This was based on promising results 
from earlier phase clinical trials, where PD-L1 seemed to 
be a predictive marker of response to atezolizumab in this 
setting (24). All these factors might have influenced the 
outcome and failure of IMvigor211 to proof superiority of, 
the clinically active substance, atezolizumab over second line 
chemotherapy in a phase III trial.
Nevertheless, pembrolizumab is the only CPI with level 
1 evidence of superiority over chemotherapy in second line 
treatment of mUC as proven in KEYNOTE-045 so far 
(10,11). The rapidly developing treatment landscape giving 
hope for our patients suffering from UC and urges the 
necessity to develop a biomarker driven clinical decision-
Figure 1 Proposed treatment algorithm based on current evidence from clinical trials. 1, FDA approved in platin ineligible pts irrespective 
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making strategy, since by far not all patients benefit from 
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